Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.
(Iran AND ("Novel Coronavirus" OR COVID-19 OR SARS-CoV-2 OR 2019-nCoV))
448 results
  • Effects of host genetic variations on response to, susceptibility and severity of respiratory infections. [Review]
    Biomed Pharmacother. 2020 May 29; 128:110296.Ghafouri-Fard S, Noroozi R, … Sanak M
  • The recent outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created a global crisis, necessitating the identification of genetic factors that modulate the risk of disorder or its severity. The current data about the role of genetic risk factors in determination of rate of SARS-CoV-2 infection in each ethnic group and the severity of disorder is limited. Moreover, s…
  • Pediatric coronavirus disease 2019 (COVID-19): An insight from west of Iran. [Journal Article]
    North Clin Istanb. 2020; 7(3):284-291.Soltani J, Sedighi I, … Nahidi S
  • CONCLUSIONS: COVID-19 is not uncommon in children and could have different presentations. Concomitant use of RT-PCR and chest CT scans in symptomatic cases recommended as a modality of choice to diagnose the disease. Routine laboratory tests, like many other viral infections, may not show significant or specific changes. The superimposed bacterial infection seems not the determinant of clinical outcomes as most patients had a negative evaluation by specific laboratory tests for bacterial infections; got improved dramatically with a short or no antibiotic therapy.
  • Oral saliva and CVID-19. [Review]
    Oral Oncol. 2020 May 27; 108:104821.Baghizadeh Fini M
  • Outbreak pneumonia announced in Wuhan, China, in December 2019, had its causative factor classified as a new coronavirus (SARS-CoV-2). Since saliva can host several viruses including SARS-CoV-2, the transmission chance of viruses through saliva, particularly those causing respiratory infections, is unavoidable. COVID-19 can be detected through salivary diagnostic testing which has lots of advanta…
  • COVID-19: Transmission, Prevention, and Potential Therapeutic Opportunities. [Review]
    Clin Chim Acta. 2020 May 28 [Online ahead of print]Lotfi M, Hamblin MR, Rezaei N
  • The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best ap…
  • The need for fully bio-based facemasks to counter coronavirus outbreaks: A perspective. [Journal Article]
    Sci Total Environ. 2020 May 22; 736:139611.Das O, Neisiany RE, … Ramakrishna S
  • The onset of coronavirus pandemic has sparked a shortage of facemasks in almost all nations. Without this personal protective equipment, healthcare providers, essential workers, and the general public are exposed to the risk of infection. In light of the aforementioned, it is critical to balance the supply and demand for masks. COVID-19 will also ensure that masks are always considered as an esse…
  • Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? [Journal Article]
    Dermatol Ther. 2020 May 30 [Online ahead of print]Seirafianpour F, Mozafarpoor S, … Goodarzi A
  • The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifyll…
  • Cytokine storm in COVID-19 and parthenolide: preclinical evidence. [Letter]
    Phytother Res. 2020 May 30 [Online ahead of print]Bahrami M, Kamalinejad M, … Dadmehr M
  • A group of patients with pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were reported from China in December 2019. Although several antiviral drugs are widely tested, none of them has been approved as specific antiviral therapy for coronavirus disease 2019 (COVID-19). Accumulating evidence established a hyperinflammatory states or cytokine storm in COVID-19. Amon…
  • The involvement of the central nervous system in patients with COVID-19. [Review]
    Rev Neurosci. 2020 May 28 [Online ahead of print]Saleki K, Banazadeh M, … Rezaei N
  • Coronaviruses disease (COVID-19) has caused major outbreaks. A novel variant, SARS-CoV-2, is responsible for COVID-19 pandemic. Clinical presentations and pathological mechanisms of COVID-19 are broad. The respiratory aspect of the disease has been extensively researched. Emerging studies point out the possibility of the central nervous system (CNS) involvement by COVID-19. Here, we discuss the c…
  • Non-steroidal anti-inflammatory drugs in management of COVID-19; a systematic review on current evidence. [Review]
    Int J Clin Pract. 2020 May 27 [Online ahead of print]Yousefifard M, Zali A, … Safari S
  • CONCLUSIONS: Although based on existing evidence, NSAIDs have been effective in treating respiratory infections caused by influenza and rhinovirus, since there is no clinical trial on COVID-19 and case-reports and clinical experiences are indicative of elongation of treatment duration and exacerbation of the clinical course of patients with COVID-19, it is recommended to use substitutes such as acetaminophen for controlling fever and inflammation and be cautious about using NSAIDs in management of COVID-19 patients until there are enough evidence. Naproxen may be a good choice for future clinical trials.
New Search Next